Age aspects of rehabilitation and treatment of osteosarcoarthrosis
Background: In older age groups, the problem of osteoporosis is becoming more urgent and acute, as the development of bone fragility leads to numerous fractures and the development of a disabling condition, increasing mortality. Regardless of the presence of osteoporosis, each person accumulates polymorbidity, which aggravates the course and destruction of bone and cartilage tissue. New associated conditions appear, such as osteoarthrosarcoporosis. The aim of the study: To assess the positive pleiotropic effects of antiresonances patients in older age taking into account the development of chronic age-associated pathologies and the presence of osteoarthrosis. To develop treatment and prevention programs for these patients in order to reduce polypragmasia. Materials and methods: In order to identify the positive pleiotropic effects of antiresorbents in older patients, we formed two groups of elderly patients. Taking into account the chronization of age-associated pathologies, we selected patients with impaired glucose tolerance and osteoarthrosarcoporosis. The average age of the patients was 67.9±0.7 years. Calcemin drug was prescribed to the first group of patients (n=34). The second group of patients (n=36) was treated with Calcemin and the zoledronic acid preparation. Detection of positive pleiotropic effects of antiresorbents in older patients was determined by the dynamics of phosphorus and calcium metabolism, the dynamics of the state of muscle tissue, and the need for hypoglycemic therapy. Results: The data obtained indicate a positive pleiotropic effect of zoledronic acid on calcium metabolism in older patients with osteoarthrosarcoporosis and impaired glucose tolerance. Positive pleiotropic effects of drugs containing zoledronic acid were expressed in an increase in muscle strength by 1.6 times, which is a prevention of the progression and development of sarcopenia in these patients, reducing the degree of pain in the vertebral column by 1.4 times and in the bones by 1.6 times, which directly affects the quality of life of older patients. A decrease in the volume of osteoporetic therapy in older patients with osteoarthrosarcoporosis can be considered as another positive pleiotropic effect of the use of drugs containing zolendronic acid. Conclusion: In the management of older patients with osteoarthrosarcoporosis, it is advisable to include long-term use of drugs containing zolendronic acid, since they have pleiotropic effects.